SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-025580
Filing Date
2022-05-11
Accepted
2022-05-11 16:05:57
Documents
45
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 f10q0322_tffpharma.htm   iXBRL 10-Q 363368
2 AMENDED AND RESTATED PATENT LICENSE AGREEMENT DATED APRIL 20, 2022 BETWEEN THE R f10q0322ex10-1_tffpharma.htm EX-10.1 335900
3 CERTIFICATION f10q0322ex31-1_tffpharma.htm EX-31.1 11777
4 CERTIFICATION f10q0322ex31-2_tffpharma.htm EX-31.2 11813
5 CERTIFICATION f10q0322ex32-1_tffpharma.htm EX-32.1 5529
6 GRAPHIC image_001.jpg GRAPHIC 2967
  Complete submission text file 0001213900-22-025580.txt   2683658

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE tffp-20220331.xsd EX-101.SCH 32741
8 XBRL CALCULATION FILE tffp-20220331_cal.xml EX-101.CAL 20625
9 XBRL DEFINITION FILE tffp-20220331_def.xml EX-101.DEF 120813
10 XBRL LABEL FILE tffp-20220331_lab.xml EX-101.LAB 257395
11 XBRL PRESENTATION FILE tffp-20220331_pre.xml EX-101.PRE 129793
39 EXTRACTED XBRL INSTANCE DOCUMENT f10q0322_tffpharma_htm.xml XML 184581
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39102 | Film No.: 22913683
SIC: 2834 Pharmaceutical Preparations